HANGZHOU, China, Dec. 1 Tigermed Consulting Co., Ltd,a leading Contract Research Organization (CRO) in China, announced that it hasestablished a subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd, with CentralSouth University (CSU). The establishment of Tigermed Xiangya marksTigermed's participation in the construction of a nationwide first-rate PhaseI Clinical Laboratory, and further substantiates Tigermed's service ability indrug pre-clinical studies and pharmaceutical analysis. This new cooperationallows Tigermed to provide more extensive and comprehensive outsourcingclinical services for Multinational Pharmaceutical Corporations and LocalResearch Institutions in the research and development of innovative drugs.
Tigermed, staffed with a team of 100 plus professionals, is dedicated toproviding such all-round services as Phase I-IV clinical trials, datamanagement & statistical analysis and regulatory affairs, and Tigermed hasaccumulated outstanding experience in the clinical trials of innovative drugs.In July 2008, financed by Qiming Ventures, an internationally renowned venturecapital organization, Tigermed entered into a period of rapid expansion.
Xiangya Medical College, predecessor of Xiangya Medical School of CSU, wasfounded in 1914 as one of the early western medicine colleges and universitiesin China, and enjoyed a high reputation as "South Xiangya, North Union",widely recognizing that Xiangya Medical College in the south and Peking UnionMedical College in the north of China are the most two famous medicalinstitutions. Currently, Xiangya Medical School of CSU has three affiliatedtertiary hospitals, 8 clinical colleges and 24 stable teaching bases. Phase IClinical Laboratory of the Drug Clinical Trial Agency in the third XiangyaHospital of CSU is one of the first groups of Laboratories passing preliminaryexamination.
Tigermed Xiangya has three Evaluation Centers: the Drug ClinicalEvaluation Center (DCEC), Pharmaceutical Analysis Center (PAC) and DrugPre-clinical Evaluation Center (DPEC). DCEC mainly cooperates with the thirdXiangya Hospital of CSU to conduct Phase I clinical trials for new drugs, andPharmacokinetics (PK) and Bioequiavailability (BE) studies in other stages ofclinical trials. PAC is chiefly responsible for the studies related topharmaceutical analysis. DPEC is principally in charge of PK screening ofcompound candidates; PK studies, Pharmacodynamics (PD) studies, qualityspecification studies, and manufacturing process studies during pre-clinicalstudies.
Professor Cheng Zeneng, Deputy Dean of the School of Pharmacy of CSU,Director of Drug Metabolism and Pharmacokinetics Research Institute, DeputyDirector of Phase I Clinical Laboratory of the Drug Clinical Trial Agency inthe third Xiangya Hospital of CSU, expressed, "CSU and its affiliatedhospitals are equipped with high technologies and abundant resources, incomplementary, Tigermed has sufficient funds and rich management expertise, sowe are quite confident of building up Tigermed Xiangya as a leading DrugClinical Evaluation Center in China."
"To set up Tigermed Xiangya is a significant move for us to complete ourclinical service chain and this union of two titans will tremendously boostTigermed's serviceability in Phase I clinical trials," comments Ms CaoXiaochun, Vice President of Tigermed, "We are looking forward to the greatfuture of Tigermed Xiangya, and it will be the first trial and a uniquepioneering effort in China's CRO industry".For more information, please contact: Zeng Haiyan Tel: +86-571-8998-6792 Email: firstname.lastname@example.org
SOURCE China Medicine Corporation